1-Methoxy-1-formylessigsaeureaethylester | 62836-98-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Methoxy-1-formylessigsaeureaethylester
• 英文别名: 2-methoxy malonaldehyde；Ethyl 2-methoxy-3-oxopropanoate
• CAS: 62836-98-0
• 化学式: C₆H₁₀O₄
• 分子量: 146.143
• InChiKey: OFBNJEUAEZLKHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲氧基乙酸乙酯 、 甲酸乙酯 在 sodium 作用下， 以 乙醚 为溶剂， 反应 4.5h， 生成 1-Methoxy-1-formylessigsaeureaethylester
  参考文献：
  名称：

  WO2008/40778

  摘要：

  公开号：

文献信息

• Nitrogen-containing heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：US20020103210A1

  公开（公告）日：2002-08-01

  A compound of the formula: 1 wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R 1 , R 2 and R 3 each is (i) H or (ii) a group bound via C, N, O or S; R 4 is a group bound via C; R 5 is H or a group bound via C or O; R 6 is H or a group bound via C; R 7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.

  化合物的公式为1，其中A和D中的一个是N，另一个是C，或者两个都是N；B是N或C；m为0-3；R1，R2和R3各自是（i）H或（ii）通过C，N，O或S结合的基团；R4是通过C结合的基团；R5是H或通过C或O结合的基团；R6是H或通过C结合的基团；R7是可以被取代的同源或异源环状基团；或其盐具有出色的促性腺激素释放激素拮抗活性，并可用作预防或治疗性激素依赖性疾病等的药物。
• CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS
  申请人：Raboisson Pierre Jean-Marie Bernard

  公开号：US20090247523A1

  公开（公告）日：2009-10-01

  The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.

  本发明涉及使用羧酰胺4-[(4-吡啶基)氨基]-嘧啶作为HCV复制抑制剂，以及它们在旨在治疗或对抗HCV感染的制药组合物中的应用。
• IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS
  申请人：Eastwood Paul Robert

  公开号：US20130216498A1

  公开（公告）日：2013-08-22

  New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  本发明揭示了具有化学式（I）的新咪唑吡啶衍生物，以及它们的制备方法，包括它们的药物组合物和它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• Pyrimidine compounds
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0180298A2

  公开（公告）日：1986-05-07

  Compounds of the formula (I) :- (1) and their salts are histamine H,-antagonists, wher in: R° is 2-guanidinothiazol-4-yl or a group R 1R2N(CHn-Z-wherein R1 and R2 are independently hydrogen, C1-6alkyl, phenyl(C1-6)alkyl, furanyl(C1-6)alkyl, thienyl(C1-8)alkyl, C3-10 cycloalkyl, hydroxy(C2-6)alkyl, or halo(C 2-6)alkyl (wherein said hydroxy and halo groups are not substituted on the carbon atom adjacent to the nitrogen atom); or R1 and R2 together represent - (OH2)r - wherein r is 4 to 7, to form together with the nitrogen atom to which they are attached a 5-8 membered saturated ring; n is an integer from 1 to 6; Z is 2,5-furanyl, 2,5-thienyl, 2,4-pyridyl wherein the R1R2N(CH2)n group is in the 4-position, 2,4-thiazolyl wherein the R1R2N(CH2)n group is in the 2-position, or 1,3- or 1,4-phenylene; m is one; or if Z is pyridyl or phenylene m may also be zero; Y is oxygen, sulphur or methylene; or if Z is furanyl, thienyl or thiazolyl Y may also be a bond; p is two, three or four; q is zero c one; R3 is hydrogen or C1-6alkyl; and R4 is hydrogen, optionally substituted C1-6alkyl, C3-10-cycloalkyl, C3-10CY- cloalkyl(C1-6)alkyl, C2-6alkenyl or C2-6alkynyl,and when q is zero R4 may also be -(CH,)sB wherein s is 1 to 6 and B is optionally substituted aryl or heteroaryl. Pharmaceutical compositions containing them are described as are processes for their preparation.

  式(I):-的化合物 (1) 及其盐类是组胺 H拮抗剂，其中：R° 是 2-胍基噻唑-4-基或基团 R 1R2N(CHn-Z- 其中 R1 和 R2 独立地是氢、C1-6烷基、苯基(C1-6)烷基、呋喃基(C1-6)烷基、噻吩基(C1-8)烷基、C3-10 环烷基、羟基(C2-6)烷基或卤代(C 2-6)烷基（其中所述羟基和卤代基团未在邻近氮原子的碳原子上被取代）；或 R1 和 R2 共同代表-(OH2)r-，其中 r 为 4 至 7，与所连接的氮原子一起形成 5-8 位饱和环；n 为 1 至 6 的整数；Z 是 2,5-呋喃基、2,5-噻吩基、2,4-吡啶基（其中 R1R2N(CH2)n 基团位于 4 位）、2,4-噻唑基（其中 R1R2N(CH2)n 基团位于 2 位）或 1,3-或 1,4-亚苯基；m为1；或者，如果Z为吡啶基或亚苯基，m也可以为0；Y为氧、硫或亚甲基；或者，如果Z为呋喃基、噻吩基或噻唑基，Y也可以是键；p为2、3或4；q为0 c为1；R3为氢或C1-6烷基；R4为氢、任选取代的C1-6烷基、C3-10-环烷基、C3-10CY-环烷基（C1-6）烷基、C2-6烯基或C2-6炔基，当q为0时，R4也可以是-(CH,)sB，其中s为1至6，B为任选取代的芳基或杂芳基。 本文还介绍了含有它们的药物组合物及其制备工艺。
• WO2006/105222
  申请人：——

  公开号：——

  公开（公告）日：——